Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03268005 · ClinicalTrials.gov registry record · Phase 3
Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 Diabetes
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,264
- Enrollment target
NCT03268005 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 1,264 participants.
The verdict
NCT03268005, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,264 participants
- Enrollment target
Study Summary
The study compares 2 medicines for type 2 diabetes: fast-acting insulin aspart (a new medicine) and NovoRapid®/NovoLog® (a medicine doctors can already prescribe). Fast-acting insulin aspart will be tested to see how well it works and if it is safe. Participants will get either fast-acting insulin aspart or NovoRapid®/ NovoLog® - which treatment you get is decided by chance. Both medicines will be taken together with insulin degludec. Participants will need to take 1 injection 4 times every day (all insulins will be provided in pens). The study will last for about 8 months (34 weeks).
Interventions
- DRUG Metformin
- DRUG Insulin aspart
- DRUG Faster-acting insulin aspart
- DRUG Insulin degludec
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,264 participants |
| Start Date | 2017-09-19 |
| Est. Completion | 2019-01-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03268005
The ClinicalTrials.gov registry entry for NCT03268005 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,264 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Metformin is the first listed.
NCT03268005 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03268005 about?
NCT03268005 is a clinical study titled "Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 Diabetes". The study compares 2 medicines for type 2 diabetes: fast-acting insulin aspart (a new medicine) and NovoRapid®/NovoLog® (a medicine doctors can already prescribe). Fast-acting insulin aspart will be tested to see how well it works and if it is safe. Participants will get either fast-acting insulin a...
What is the current status of trial NCT03268005?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,264 participants. The study started on 2017-09-19. Estimated completion is 2019-01-29.
What interventions are being tested in trial NCT03268005?
The interventions under investigation include: Metformin (DRUG), Insulin aspart (DRUG), Faster-acting insulin aspart (DRUG), Insulin degludec (DRUG).
Who is sponsoring clinical trial NCT03268005?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.